The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Open accessAbstract
Background Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death.Scope of review In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses.Major conclusions Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo.General significance The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, a variety of studies confirmed an improved anti-cancer drug uptake upon conjugation to a TfR monoclonal antibody [101,102,103].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–232 of 232
Bergamaschi, G., Cazzola, M., Dezza, L., Savino, E., Consonni, L., & Lappi, D. A. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb04218.x · Cited by 29
Development of a transferrin receptor-targeting HVJ-E vector
Shimbo, T., Kawachi, M., Saga, K., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.135 · Cited by 28
Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin, T. W., & Raso, V. (1991) · PubMed · Cited by 28
Pirker, R., FitzGerald, D. J., Willingham, M. C., et al. (1988) · PubMed · Cited by 27
Cimini, A., Mei, S., Benedetti, E., Laurenti, G., Koutris, I., Cinque, B., Cifone, M. G., Galzio, R. J., Pitari, G., Leandro, L. D., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22805 · Cited by 26
Bjorn, M. J., & Groetsema, G. (1987) · PubMed · Cited by 26
Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate
Lai, B.-T., Gao, J., & Lanks, K. W. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050722 · Cited by 25
Rathore, D., & Batra, J. K. (1997) · Biochemical Journal · doi:10.1042/bj3240815 · Cited by 24
Dreier, T., Lode, H. N., Xiang, R., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980020e · Cited by 24
Overproduction of fungal ribotoxin α-sarcin in Escherichia coli: generation of an active immunotoxin
Rathore, D., Nayak, S. K., & Batra, J. K. (1997) · Gene · doi:10.1016/s0378-1119(96)00696-8 · Cited by 23
Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation
Xu, S., Liu, Y., Tai, H.-C., et al. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.053 · Cited by 23
Asai, T., Trinh, R. K., Ng, P. P., et al. (2004) · Biomolecular Engineering · doi:10.1016/j.bioeng.2004.10.001 · Cited by 23
Hatano, T., Ohkawa, K., & Matsuda, M. (1993) · Tumor Biology · doi:10.1159/000217841 · Cited by 22
Cytotoxic onconase and ribonuclease a chimeras: comparison andin vitrocharacterization
Rybak, S. M., Newton, D. L., Mikulski, S. M., et al. (1993) · Drug Delivery · doi:10.3109/10717549309031335 · Cited by 22
Pearson, J. W., Hedrick, E., Fogler, W. E., et al. (1990) · PubMed · Cited by 21
Cazzola, M., Bergamaschi, G., Dezza, L., et al. (1991) · PubMed · Cited by 19
Generation of Active Immunotoxins Containing Recombinant Restrictocin
Rathore, D., & Batra, J. K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0697 · Cited by 19
Gosselaar, P. H., Van‐Dijk, A. J. G., GAST, G. C. D., Polito, L., Bolognesi, A., Vooijs, W. C., Verheul, A. F. M., Krouwer, H. G. J., & Marx, J. J. M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1061.x · Cited by 19
Schwarzenberger, P. O., Huang, W., Oliver, P., Theodossiou, C., Osidipe, T., & Kolls, J. K. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200102000-00004 · Cited by 18
Goyal, A., & Batra, J. K. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3450247 · Cited by 18
Kircheis, R., Küpcü, Z., Wallner, G., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700183 · Cited by 17
Barabás, K., SIZENSKY, J. A., & Faulk, W. P. (1991) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1991.tb01078.x · Cited by 17
Characterization of a translation inhibitory protein from Luffa aegyptiaca
Ramakrishnan, S., Enghlid, J. J., Bryant, H. L., et al. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92462-5 · Cited by 16
Béjaoui, N., Page, M. M., & Noël, C. (1992) · PubMed · Cited by 14
Penacho, N., Filipe, A. D. S., Simões, S., et al. (2008) · The Journal of Membrane Biology · doi:10.1007/s00232-008-9092-x · Cited by 12
Griffin, T. W., Stocl, M., Collins, J., et al. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199201000-00002 · Cited by 11
Schwarzenberger, P. O., Hunt, J. D., Robert, E., et al. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8563-8571.1997 · Cited by 10
Active tumor-targeted delivery of PEG-protein via transferrin–transferrin-receptor system
Jiang, Y., Tang, G., Hong, M., et al. (2007) · Journal of drug targeting · doi:10.1080/10611860701603414 · Cited by 9
Enhancement of gene delivery to cancer cells by a retargeted adenovirus.
Oh, K. S., Engler, J. A., & Joung, I. (2005) · PubMed · Cited by 9
Li, J., Weng, X., Liang, Z., Zhong, M., Chen, X., Lu, S., Sun, W., Song, Y., Wu, X., & Shen, G. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.008 · Cited by 7
Elliott, R. L., & Head, J. F. (2006) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.21.138 · Cited by 5
In vivo compatibility and degradation of crosslinked gelatin gels incorporated in knitted Dacron
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-4636(200007)51:1 · Cited by 4
Flagged first, then by citations
Cited by
Sorted by citations
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“These therapeutic antibodies, as well as targeting antibodies such as 2C5 [2] and anti-transferrin receptor mAbs [99-101], can be conjugated to various nanoparticles to improve efficacy and increase binding affinity to the cancer cells.”
BackgroundSelf-citationLipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Metadata
- Authors
- Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L.
- Affiliations
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- University of California, Los Angeles (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Helguera, Gustavo
- Penichet, Manuel L.
- ORCID
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 1820
- Issue
- 3
- Pages
- 291-317
- ISSN
- 0304-4165 (ISSN-L)
- PMC
- PMC3500658
- OpenAlex
- W2027437657
- Cited by
- 807
- References
- 232
- Citations by year
- 2026: 37 · 2025: 50 · 2024: 69 · 2023: 55 · 2022: 57 · 2021: 65 · 2020: 69 · 2019: 75 · 2018: 64 · 2017: 52 · 2016: 59 · 2015: 55 · 2014: 39 · 2013: 47 · 2012: 14
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - General Subjects (publishedVersion)
- PubMed (publishedVersion)
- Conicet (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- CONICET Digital (CONICET) (submittedVersion, cc-by-nc-nd)
- Funders
- NIH/NCI (R01CA136841, R01CA107023, R01CA123495, R01CA57152, U01CA151815, K01CA138559)
- Howard Hughes Medical Institute Gilliam Fellowship
- Whitcome Fellowship of the Molecular Biology Institute at UCLA
- National Agency for Promotion of Science and Technology (ANPCyT-FONARSEC PICT-PRH 2008-00315)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- transferrin receptor, targeted cancer therapy, receptor-mediated drug delivery, transferrin, nanoparticles, viral vectors, iron absorption, cancer cell death
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Carrier Proteins, Genetic Vectors, Humans, Iron, Neoplasms, Receptors, Transferrin, Drug Delivery Systems, Apoptosis, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
